drugset / Trial / NCT02037477

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

NCT02037477

Phase 3 Completed 20 enrolled Takeda
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate the acid-inhibitory effect of multiple oral doses of Vonoprazan (TAK-438) and the relative effect of vonoprazan versus two controls (esomeprazole and rabeprazole sodium) in healthy Japanese adult male participants with the CYP2C19 extensive metabolizer (EM) genotype.

Timeline

Start
2014-01
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 20 mg Oral
Subject Rabeprazole Small molecule 10 mg Oral
Subject Vonoprazan Other / unclassified 20 mg Oral

Indications

No indication recorded.